About Us

We are a team of passionate scientists and drug development experts striving to create patient-centric therapies that restore the immune system to its natural state. We are immune system experts that seek to either downregulate or upregulate the immune system to treat disease. Our immune system expertise has led us to develop breakthroughs in three main areas.

Autoimmune conditions can cause the immune system to overreact and attack self, causing damage to the body. Current treatment options result in immune suppression leaving patients immune compromised and susceptible to opportunistic infection. In addition, many of the currently utilized therapies are costly, time consuming to administer and/or are prescribed under specialized programs to manage serious adverse events of such therapies (REMS) limiting patient access to those treatments.

Immune tolerance induction may offer an alternative to the traditional approaches to treating autoimmune diseases. LAPIX has developed a first in class and, what it believes, will be best in class antigen-agnostic immune tolerance treatments for various autoimmune conditions including Neuroautoimmune disease, Rheumatological disease as well as GI autoimmune diseases that will be delivered to the patient via novel and proprietary orally bioavailable small molecules therapies. These therapies are not immune suppressive and act as an agonist of Tim receptors, resulting in an expansion of the population of natural and inducible regulatory T-cells. Further, these therapies down-regulate pathogenic Th17, restoring the natural balance in the immune system.

In immuno-oncology, we have developed orally bioavailable small molecules as a monotherapy for checkpoint restoration that works upstream of current checkpoint inhibitors like PD-1. Our pre-clinical data has shown that by targeting Tim-3 with LPX-IO, we down-regulate the expression of KLRG-1, Tim3, PD-1 and CLTA-4 while also restoring the tumor fighting ability of CD8+ T-cells. Our pre-clinical animal models have demonstrated that our therapy has the ability to shrink tumors, not simply inhibit growth.

LAPIX has also developed a way to tolerize the immune system to gene therapy. Three in four patients develop an immune response to gene therapy treatments. This immune response is a major safety issue and can limits patients to receiving one treatment of gene therapy or no treatment at all. LAPIX will license its technology for tolerization to gene therapy on a target by target basis.

Finally, out of a need for animal models that better project and reflect the human response to therapies, we have developed our XenoImmune™ humanized mouse model that mimics the human immune system.